Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 5, pp 1250–1256 | Cite as

Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis

  • Leigh Anne Keough
  • Amy Krauss
  • Joanna Q. HudsonEmail author
Research Article
  • 186 Downloads

Abstract

Background Patients requiring SLED are often critically ill and/or hemodynamically unstable, and often need antibiotic therapy for life-threatening infections. Antibiotic dosing recommendations for intermittent hemodialysis and continuous renal replacement therapy are not appropriate for SLED and there is substantial concern for under dosing. Objective To characterize the adequacy of antibiotic dosing during SLED. Setting: Inpatient adult acute care hospital. Methods A retrospective chart review was performed for the period of October 2010 to August 2013 to identify patients who received SLED and at least one of the selected antibiotics: cefepime, daptomycin, piperacillin/tazobactam, meropenem, and vancomycin. Dosing regimens were evaluated each day the patient was receiving one of these antibiotics concurrently with SLED. The administered antibiotic dosing regimens were defined as “adequate” or “inadequate” based on recommendations available in the literature. Main outcome measure The percentage of adequate antibiotic days for each antibiotic. Results Antibiotic regimens were evaluated for a total of 51 patients: 35 (69%) with acute kidney injury, 16 (31%) with end-stage renal disease, mean SLED duration 9.3 ± 1.7 h. The total percent of adequate antibiotic days were: vancomycin 86%, cefepime 62%, daptomycin 58%, meropenem 35%, and piperacillin/tazobactam 20%. Under dosing accounted for 63% of the days antibiotic dosing was considered inadequate. Conclusion: Antibiotic dosing was frequently inadequate, especially for antibiotics requiring more frequent dosing, suggesting a high potential for subtherapeutic levels during the majority of time critically ill patients are requiring SLED.

Keywords

Antibiotics Dialysis Drug removal Kidney disease Sustained low-efficiency dialysis United States 

Notes

Acknowledgements

The authors would like to acknowledge the assistance of the Dr. Joyce Broyles at Methodist University Hospital for assistance with this project.

Funding

No financial support was provided for this study.

Conflicts of interest

The authors have no conflicts of interest to report.

References

  1. 1.
    Kovacs B, Sullivan KJ, Hiremath S, Patel RV. Effect of sustained low efficient dialysis versus continuous renal replacement therapy on renal recovery after acute kidney injury in the intensive care unit: a systematic review and meta-analysis. Nephrology. 2017;22:343–53.CrossRefGoogle Scholar
  2. 2.
    Nash DM, Przech S, Wald R, O’Reilly D. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care. 2017;41:138–44.CrossRefGoogle Scholar
  3. 3.
    Marshall MR, Golper TA. Low-efficiency acute renal replacement therapy: role in acute kidney injury. Semin Dial. 2011;24:142–8.CrossRefGoogle Scholar
  4. 4.
    Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int. 2001;60:777–85.CrossRefGoogle Scholar
  5. 5.
    Jamal JA, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit Care Med. 2014;42:1640–50.CrossRefGoogle Scholar
  6. 6.
    Roberts DM, Liu X, Roberts JA, Nair P, Cole L, Roberts MS, et al. A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care. 2015;19:84.CrossRefGoogle Scholar
  7. 7.
    Scoville BA, Mueller BA. Medication dosing in critically ill patients with acute kidney injury treated with renal replacement therapy. Am J Kidney Dis. 2013;61:490–500.CrossRefGoogle Scholar
  8. 8.
    Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller PD, Olsen KM. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med. 2011;39:560–70.CrossRefGoogle Scholar
  9. 9.
    Harris LE, Reaves AB, Krauss AG, Griner J, Hudson JQ. Evaluation of antibiotic prescribing patterns in patients receiving sustained low-efficiency dialysis: opportunities for pharmacists. Int J Pharm Pract. 2013;21:55–61.CrossRefGoogle Scholar
  10. 10.
    Mei JP, Ali-Moghaddam A, Mueller BA. Survey of pharmacists’ antibiotic dosing recommendations for sustained low-efficiency dialysis. Int J Clin Pharm. 2016;38:127–34.CrossRefGoogle Scholar
  11. 11.
    Shaw AR, Chaijamorn W, Mueller BA. We underdose antibiotics in patients on CRRT. Semin Dial. 2016;29:278–80.CrossRefGoogle Scholar
  12. 12.
    Shaw AR, Mueller BA. Antibiotic dosing in continuous renal replacement therapy. Adv Chronic Kidney Dis. 2017;24:219–27.CrossRefGoogle Scholar
  13. 13.
    Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, et al. Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative. Clin J Am Soc Nephrol. 2015;10:159–64.CrossRefGoogle Scholar
  14. 14.
    Jamal JA, Mueller BA, Choi GY, Lipman J, Roberts JA. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis. 2015;82:92–103.CrossRefGoogle Scholar
  15. 15.
    Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo simulations to determine optimal carbapenem dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. J Clin Pharmacol. 2016;56:1277–87.CrossRefGoogle Scholar
  16. 16.
    Gharibian KN, Mueller BA. Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach. Clin Nephrol. 2016;86:43–50.CrossRefGoogle Scholar
  17. 17.
    Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2011;80:1122–37.CrossRefGoogle Scholar
  18. 18.
    Sinnollareddy MG, Roberts MS, Lipman J, Peake SL, Roberts JA. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. J Antimicrob Chemother. 2018;73(6):1647–50.CrossRefGoogle Scholar
  19. 19.
    Braune S, Konig C, Roberts JA, Nierhaus A, Steinmetz O, Baehr M, et al. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study. Crit Care. 2018;22:25.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of PharmacyVeterans Affairs Medical CenterMemphisUSA
  2. 2.Department of PharmacyGritman Medical CenterMoscowUSA
  3. 3.Department of Clinical Pharmacy and Translational ScienceUniversity of Tennessee College of PharmacyMemphisUSA
  4. 4.Department of Medicine (Nephrology)The University of Tennessee Health Science CenterMemphisUSA

Personalised recommendations